Q86WB0 (NIPA_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
January 25, 2012.
Version 79.
History...
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Nuclear-interacting partner of ALK Alternative name(s): Nuclear-interacting partner of anaplastic lymphoma kinase Short name=hNIPA Zinc finger C3HC-type protein 1 | ||||||
| Gene names |
| ||||||
| Organism | Homo sapiens (Human) | ||||||
| Taxonomic identifier | 9606 [NCBI] | ||||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 502 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Essential component of an SCF-type E3 ligase complex, SCF(NIPA), a complex that controls mitotic entry by mediating ubiquitination and subsequent degradation of cyclin B1 (CCNB1). Its cell-cycle-dependent phosphorylation regulates the assembly of the SCF(NIPA) complex, restricting CCNB1 ubiquitination activity to interphase. Its inactivation results in nuclear accumulation of CCNB1 in interphase and premature mitotic entry. May have an antiapoptotic role in NPM-ALK-mediated signaling events. Ref.6 |
| Pathway | |
| Subunit structure | Interacts with the NPM-ALK fusion protein in a tyrosine phosphorylation-dependent manner. Interacts with SKP1. Component of a SCF(NIPA) E3 complex with SKP1, RBX1 and CUL1 when not phosphorylated on Ser-354. Interacts with CCNB1. Ref.1 Ref.6 |
| Subcellular location | |
| Tissue specificity | Widely expressed. Highly expressed in heart, skeletal muscle and testis. Expressed in brain, placenta, lung, kidney, liver, pancreas, spleen, thymus, prostate, ovary small intestine and colon. Weakly or not expressed in leukocytes. Ref.1 |
| Developmental stage | Weakly expressed in G0/G1 phases, abundant during S and G2/M phases, and strongly decreases thereafter. Ref.6 |
| Domain | The F-box-like region is required for the interaction with SKP1. Ref.6 |
| Post-translational modification | Phosphorylated. Phosphorylated on Ser residues at G2/M phase, but not during S and G0 phases. May also be weakly phosphorylated on Tyr residues. Ser-354 phosphorylation, a major site during the course of cell-cycle-dedendent phosphorylation, results in its dissociation from the SCF(NIPA) complex, thereby preventing CCNB1 degradation leading to mitotic entry. Ref.1 Ref.6 Ref.7 Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.13 Ref.14 Ref.15 Ref.16 |
| Sequence similarities | Contains 1 C3HC-type zinc finger. |
| Caution | Reported to contain a F-box domain (Ref.6). Such domain is however not predicted by any detection method. |
| Sequence caution | The sequence AAF36136.1 differs from that shown. Reason: Frameshift at positions 93, 187 and 220. The sequence AAH28917.1 differs from that shown. Reason: Erroneous initiation. The sequence AAS07546.1 differs from that shown. Reason: Erroneous gene model prediction. The sequence AAS07547.1 differs from that shown. Reason: Erroneous gene model prediction. |
Ontologies
| Keywords | |
|---|---|
| Biological process | Cell cycle Cell division Mitosis Ubl conjugation pathway |
| Cellular component | Nucleus |
| Coding sequence diversity | Alternative splicing Polymorphism |
| Domain | Zinc-finger |
| Ligand | Metal-binding Zinc |
| PTM | Acetylation Phosphoprotein |
| Technical term | Complete proteome Reference proteome |
| Gene Ontology (GO) | |
| Biological process | cell division Inferred from electronic annotation. Source: UniProtKB-KW mitosisInferred from electronic annotation. Source: UniProtKB-KW |
| Cellular component | nuclear membrane Inferred from direct assay. Source: HPA |
| Molecular function | protein kinase binding Inferred from physical interaction. Source: UniProtKB zinc ion bindingInferred from electronic annotation. Source: InterPro |
| Complete GO annotation... | |
Alternative products
| This entry describes 3 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: Q86WB0-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q86WB0-2) The sequence of this isoform differs from the canonical sequence as follows: 1-49: MAAPCEGQAF...IAPEEGGVDA → MRGLPRKREAWTQPHPLEALYESLRVLE | ||||||
| Note: No experimental confirmation available. | ||||||
| Isoform 3 (identifier: Q86WB0-3) The sequence of this isoform differs from the canonical sequence as follows: 341-411: Missing. | ||||||
| Note: No experimental confirmation available. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Initiator methionine | 1 | 1 | Removed | ||||||
| Chain | 2 – 502 | 501 | Nuclear-interacting partner of ALK | PRO_0000096849 | |||||
Regions | |||||||||
| Zinc finger | 102 – 156 | 55 | C3HC-type | ||||||
| Region | 170 – 210 | 41 | F-box-like | ||||||
| Motif | 396 – 402 | 7 | Nuclear localization signal Ref.1 | ||||||
Amino acid modifications | |||||||||
| Modified residue | 2 | 1 | N-acetylalanine Ref.14 | ||||||
| Modified residue | 24 | 1 | Phosphoserine Ref.7 Ref.8 Ref.10 Ref.13 | ||||||
| Modified residue | 28 | 1 | Phosphothreonine Ref.7 Ref.8 Ref.13 | ||||||
| Modified residue | 58 | 1 | Phosphoserine Ref.14 Ref.16 | ||||||
| Modified residue | 62 | 1 | Phosphoserine Ref.14 Ref.16 | ||||||
| Modified residue | 84 | 1 | Phosphothreonine Ref.10 | ||||||
| Modified residue | 321 | 1 | Phosphoserine Ref.7 Ref.8 Ref.11 Ref.12 Ref.13 Ref.14 Ref.16 | ||||||
| Modified residue | 333 | 1 | Phosphothreonine Ref.13 | ||||||
| Modified residue | 335 | 1 | Phosphoserine Ref.13 Ref.14 Ref.16 | ||||||
| Modified residue | 338 | 1 | Phosphoserine Ref.13 Ref.14 Ref.15 Ref.16 | ||||||
| Modified residue | 344 | 1 | Phosphoserine Ref.13 Ref.14 Ref.16 | ||||||
| Modified residue | 354 | 1 | Phosphoserine Ref.1 Ref.7 Ref.13 Ref.16 | ||||||
| Modified residue | 357 | 1 | Phosphoserine Ref.13 | ||||||
| Modified residue | 359 | 1 | Phosphoserine Ref.16 | ||||||
| Modified residue | 370 | 1 | Phosphoserine Ref.9 Ref.13 Ref.16 | ||||||
| Modified residue | 384 | 1 | Phosphothreonine Ref.13 | ||||||
| Modified residue | 387 | 1 | Phosphothreonine Ref.13 Ref.14 Ref.16 | ||||||
| Modified residue | 394 | 1 | Phosphoserine Ref.13 | ||||||
| Modified residue | 395 | 1 | Phosphoserine Ref.11 Ref.12 Ref.13 Ref.14 Ref.16 | ||||||
Natural variations | |||||||||
| Alternative sequence | 1 – 49 | 49 | MAAPC…GGVDA → MRGLPRKREAWTQPHPLEAL YESLRVLE in isoform 2. | VSP_015217 | |||||
| Alternative sequence | 341 – 411 | 71 | Missing in isoform 3. | VSP_015218 | |||||
| Natural variant | 271 | 1 | T → A. Ref.5 Corresponds to variant rs1464890 [ dbSNP | Ensembl ]. | VAR_023312 | |||||
| Natural variant | 363 | 1 | R → H. Ref.5 Corresponds to variant rs11556924 [ dbSNP | Ensembl ]. | VAR_023313 | |||||
Experimental info | |||||||||
| Mutagenesis | 105 | 1 | Y → F: Does not strongly affect phosphorylation status; when associated with F-137. Ref.1 | ||||||
| Mutagenesis | 137 | 1 | Y → F: Does not strongly affect phosphorylation status; when associated with F-105. Ref.1 | ||||||
| Mutagenesis | 170 – 171 | 2 | LP → FM: Abolishes interaction with SKP1. | ||||||
| Mutagenesis | 354 | 1 | S → A: Strongly reduces phosphorylation and induces the formation of a constitutive SCF(NIPA) E3 complex that degrades CCNB1 at G2/M phase and delays mitotic entry. Ref.1 Ref.6 | ||||||
| Mutagenesis | 398 – 401 | 4 | RKAK → AAAA: Induces a complete cytoplasmic redistribution. Ref.1 | ||||||
| Mutagenesis | 399 | 1 | K → P: Induces a partial cytoplasmic redistribution. Ref.1 | ||||||
| Sequence conflict | 179 | 1 | V → I in BAB14024. Ref.3 | ||||||
| Sequence conflict | 278 | 1 | K → R in AAF36136. Ref.2 | ||||||
Sequences
| ||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)." Ouyang T., Bai R.-Y., Bassermann F., von Klitzing C., Klumpen S., Miething C., Morris S.W., Peschel C., Duyster J. J. Biol. Chem. 278:30028-30036(2003) [PubMed: 12748172] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, NUCLEAR LOCALIZATION SIGNAL, INTERACTION WITH NPM-ALK FUSION PROTEIN, PHOSPHORYLATION AT SER-354, MUTAGENESIS OF TYR-105; TYR-137; SER-354; LYS-399 AND 398-ARG--LYS-401. |
| [2] | "Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells." Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G., Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W., Tao J., Huang Q.-H., Zhou J., Hu G.-X. Chen Z.Genome Res. 10:1546-1560(2000) [PubMed: 11042152] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). Tissue: Umbilical cord blood. |
| [3] | "Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. Sugano S.Nat. Genet. 36:40-45(2004) [PubMed: 14702039] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). Tissue: Mammary gland. |
| [4] | "The DNA sequence of human chromosome 7." Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., Delehaunty K.D., Miner T.L. Wilson R.K.Nature 424:157-164(2003) [PubMed: 12853948] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [5] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), VARIANTS ALA-271 AND HIS-363. Tissue: Kidney and Mammary gland. |
| [6] | "NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry." Bassermann F., von Klitzing C., Munch S., Bai R.-Y., Kawaguchi H., Morris S.W., Peschel C., Duyster J. Cell 122:45-57(2005) [PubMed: 16009132] [Abstract] Cited for: FUNCTION, PHOSPHORYLATION, DEVELOPMENTAL STAGE, DOMAIN, INTERACTION WITH SKP1 AND CCNB1, IDENTIFICATION IN SCF(NIPA) COMPLEX WITH SKP1; CUL1 AND RBX1, MUTAGENESIS OF 170-LEU-PRO-171 AND SER-354. |
| [7] | "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Cell 127:635-648(2006) [PubMed: 17081983] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24; THR-28; SER-321 AND SER-354, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [8] | "A probability-based approach for high-throughput protein phosphorylation analysis and site localization." Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P. Nat. Biotechnol. 24:1285-1292(2006) [PubMed: 16964243] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24; THR-28 AND SER-321, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [9] | "Evaluation of the low-specificity protease elastase for large-scale phosphoproteome analysis." Wang B., Malik R., Nigg E.A., Korner R. Anal. Chem. 80:9526-9533(2008) [PubMed: 19007248] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [10] | "Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column." Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y. Anal. Sci. 24:161-166(2008) [PubMed: 18187866] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND THR-84, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [11] | "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis." Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III J. Proteome Res. 7:1346-1351(2008) [PubMed: 18220336] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321 AND SER-395, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [12] | "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle." Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., Greff Z., Keri G., Stemmann O., Mann M. Mol. Cell 31:438-448(2008) [PubMed: 18691976] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321 AND SER-395, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [13] | "A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed: 18669648] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24; THR-28; SER-321; THR-333; SER-335; SER-338; SER-344; SER-354; SER-357; SER-370; THR-384; THR-387; SER-394 AND SER-395, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [14] | "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach." Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S. Anal. Chem. 81:4493-4501(2009) [PubMed: 19413330] [Abstract] Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-58; SER-62; SER-321; SER-335; SER-338; SER-344; THR-387 AND SER-395, MASS SPECTROMETRY. Tissue: Embryonic kidney. |
| [15] | "Large-scale proteomics analysis of the human kinome." Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., Mann M., Daub H. Mol. Cell. Proteomics 8:1751-1764(2009) [PubMed: 19369195] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-338, MASS SPECTROMETRY. |
| [16] | "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions." Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Sci. Signal. 2:RA46-RA46(2009) [PubMed: 19690332] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-58; SER-62; SER-321; SER-335; SER-338; SER-344; SER-354; SER-359; SER-370; THR-387 AND SER-395, MASS SPECTROMETRY. Tissue: Leukemic T-cell. |
Cross-references
Sequence databases | |
|---|---|
| EMBL GenBank DDBJ | AJ537494 mRNA. Translation: CAD61161.1. AF151050 mRNA. Translation: AAF36136.1. Frameshift. AK001317 mRNA. Translation: BAA91619.1. AK022373 mRNA. Translation: BAB14024.1. AC073320 Genomic DNA. Translation: AAS07546.1. Sequence problems. AC073320 Genomic DNA. Translation: AAS07547.1. Sequence problems. AC087071 Genomic DNA. No translation available. BC011551 mRNA. Translation: AAH11551.1. BC028917 mRNA. Translation: AAH28917.1. Different initiation. |
| IPI | IPI00301421. IPI00339382. IPI00479595. |
| RefSeq | NP_057562.3. NM_016478.3. |
| UniGene | Hs.194157. |
3D structure databases | |
| ProteinModelPortal | Q86WB0. |
| ModBase | Search... |
Protein-protein interaction databases | |
| STRING | Q86WB0. |
PTM databases | |
| PhosphoSite | Q86WB0. |
Polymorphism databases | |
| DMDM | 73921220. |
Proteomic databases | |
| PRIDE | Q86WB0. |
Protocols and materials databases | |
| StructuralBiologyKnowledgebase | Search... |
Genome annotation databases | |
| Ensembl | ENST00000358303; ENSP00000351052; ENSG00000091732. |
| GeneID | 51530. |
| KEGG | hsa:51530. |
| UCSC | uc003vph.1. human. uc003vpi.1. human. uc010lma.1. human. |
Organism-specific databases | |
| CTD | 51530. |
| GeneCards | GC07M129658. |
| H-InvDB | HIX0007070. |
| HGNC | HGNC:29913. ZC3HC1. |
| HPA | HPA019089. HPA024023. |
| neXtProt | NX_Q86WB0. |
| PharmGKB | PA134931869. |
| GenAtlas | Search... |
Phylogenomic databases | |
| GeneTree | ENSGT00390000006086. |
| HOVERGEN | HBG082030. |
| InParanoid | Q86WB0. |
| OMA | RFPLVPE. |
| OrthoDB | EOG4B2SXH. |
Gene expression databases | |
| ArrayExpress | Q86WB0. |
| Bgee | Q86WB0. |
| CleanEx | HS_ZC3HC1. |
| Genevestigator | Q86WB0. |
| GermOnline | ENSG00000091732. Homo sapiens. |
Family and domain databases | |
| InterPro | IPR013909. NIPA/Rsm1. IPR012935. Znf_C3HC-like. [Graphical view] |
| Pfam | PF08600. Rsm1. 1 hit. PF07967. zf-C3HC. 1 hit. [Graphical view] |
| ProtoNet | Search... |
Other | |
| NextBio | 55270. |
Entry information
| Entry name | NIPA_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q86WB0 Secondary accession number(s): A6NH66 Q9P0R0 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 7 Human chromosome 7: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| PATHWAY comments Index of metabolic and biosynthesis pathways |
| SIMILARITY comments Index of protein domains and families |

Clusters with